ClinicalTrials.gg
RecruitingNCT07224672ALANISUpdated Nov 3, 2026

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

A Phase 2 interventional study of Belantamab mafodotin and Cyclophosphamide in Amyloidosis, sponsored by GlaxoSmithKline. Recruiting at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 3, 2026First site in United Kingdom11 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Amyloidosis by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Amyloidosis · GlaxoSmithKline.

Planned enrollment
2nd of 10
60 · median 20
Started
2026
the only one that year
Phase 2
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Amyloidosis by GlaxoSmithKline, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 2, and was the 10th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

1 of the 10 studies in Amyloidosis by GlaxoSmithKline is open now, in 3 countries.

By country, each count listing its studies:

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Amyloidosis by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .

03

Conditions studied

  • Amyloidosis

Keywords

  • Amyloid light chain amyloidosis
  • Bortezomib
  • Cyclophosphamide
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is at least 18 years of age or the legal age of consent
  • Has confirmed newly diagnosed primary AL amyloidosis according to the following criteria:

    • Presence of an amyloid-related systemic syndrome as per consensus guidelines.
    • Positive amyloid staining by Congo red stain with green birefringence on polarized light microscopy in any tissue AND at least 1 of the following tests to confirm amyloid type as AL Characteristic appearance by electron microscopy or confirmatory immunohistochemistry or AL amyloidosis typing by mass spectrometric proteomic analysis of the amyloid deposits or amyloid-typing by immunofluorescence oEvidence of a monoclonal plasma cell proliferative disorder
  • Measurable clonal disease as defined by at least 1 of the following:

    • Serum monoclonal protein >=0.5 grams per deciliter (g/dL) by protein electrophoresis (routine serum protein electrophoresis and immunofixation performed at central laboratory),
    • Involved serum FLC >=5.0 milligram per deciliter (mg/dL) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved light chain, FLC concentrations (dFLC) >=5 mg/dL.
  • Not considered candidate for high-dose chemotherapy with stem cell transplantation (ASCT) as part of of therapy
  • Is willing to use adequate .
  • Is capable of giving signed
  • Has an performance status of 0, 1 or 2
  • Has adequate hematologic, hepatic and renal function

Exclusion criteria

Exclusion criteria:

  • Has a previous or current diagnosis of plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome or symptomatic multiple myeloma (MM), as per International Myeloma Working Group criteria for MM including the presence of lytic bone disease , plasmacytomas, or clonal BM plasma cells >=60%.
  • Has Immunoglobulin M (IgM)-related AL amyloidosis.
  • Has any form of non-AL amyloidosis, including wild type or mutated (Transthyretin amyloidosis [ATTR]) amyloidosis.
  • Has evidence of significant cardiovascular (CV) conditions as specified below:

    • (NYHA) classification IIIb or IV heart failure.
    • Heart failure that in the opinion of the investigator is caused by ischemic heart disease (e.g., prior myocardial infarction with documented history of cardiac enzyme elevation and [ECG] changes) or uncorrected valvular disease and not primarily due to AL amyloidosis cardiomyopathy.
    • In-participant admission to a hospital for unstable angina or myocardial infarction within the last 3 months prior to screening or percutaneous cardiac intervention with recent stent within last 3 months prior to screening or coronary artery bypass grafting within the last 3 months prior to screening
    • Participants with current evidence of untreated arrhythmia(s), including clinically significant ECG abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block.
    • Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillator is indicated but not placed (participants who do have a pacemaker/implantable cardioverter-defibrillator are allowed on the study).
    • Screening 12-lead ECG showing a baseline as corrected by Fridericia's formula (QTcF) >450 millisecond (msec) or >480 msec for participants with bundle branch block. Participants who have a pacemaker may be included regardless of calculated QTc interval.
    • Supine systolic blood pressure \<90 millimeters of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of >20 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion.
    • Uncontrolled hypertension.
  • Has Mayo stage 3B disease
  • Has a current corneal epithelial disease except for mild punctate keratopathy.
  • Has previous or concurrent other than AL amyloidosis, except for any other malignancy that has been considered medically stable for at least 2 yearsThe participant must not be receiving active therapy, other than hormonal therapy for this disease.
  • Has major surgery within 2 weeks prior to the first dose of study interventions or has not recovered fully from surgery.
  • Has any history of prior allogenic or autologous BM transplant or other solid organ transplant.
  • Has known immediate or delayed reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, cyclophosphamide, bortezomib, boron or mannitol
  • Has active infection or active bleeding.
  • Has intolerance or to antiviral prophylaxis.
  • Has known (HIV) infection, unless the participant can meet all of the following criteria:

    • Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load \<400 copies/milliliter (mL) Cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts >=350 cells/microliter.
    • No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months.
  • Has prior therapy for AL amyloidosis or MM, with the exception of 160 milligram (mg) dexamethasone (or equivalent ) maximum exposure prior to enrollment.
  • Has received any live or within 30 days prior to first dose of belantamab mafodotin
  • Is currently enrolled or has participated in any other clinical study involving an study intervention or any other type of interventional medical research within 28 days before enrollment.
  • Has an (ALT) value >2.5* (ULN) or >3*ULN if hepatic involvement of AL amyloidosis
  • Has a total value >1.5*ULN
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment Has documented presence of surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention, unless HBV DNA is undetectable at screening and participant receives antiviral prophylaxis or treatment.
  • Has a positive antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention unless the following criteria are met:

    • RNA test negative.
    • Successful antiviral treatment (usually 8 weeks duration), followed by a negative Hepatitis C virus RNA test after a of at least 4 weeks.
  • Chronic hepatitis B infection, with the presence of HBsAg and/or detectable hepatitis B virus deoxyribonucleic acid (HBV DNA), and hepatitis D co-infection, with hepatitis D antibody and/or RNA, within 3 months
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Dose optimization phase: Belantamab mafodotin dose level 1 + CyBorD

    Adult participants with newly diagnosed amyloid light chain (AL) amyloidosis will receive Belantamab mafodotin dose level 1 in combination with CyBorD in dose optimization phase.

    Drug: Belantamab mafodotin · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Dose optimization phase: Belantamab mafodotin dose level 2+ CyBorD

    Adult participants with newly diagnosed AL amyloidosis will receive Belantamab mafodotin dose level 2 in combination with CyBorD in dose optimization phase.

    Drug: Belantamab mafodotin · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Dose expansion phase: Belantamab mafodotin + CyBorD

    Adult participants with newly diagnosed AL amyloidosis will receive belantamab mafodotin at selected dose level from dose optimization phase in combination with CyBorD in dose expansion phase.

    Drug: Belantamab mafodotin · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Overall complete hematologic response (CHR) rate

    The overall CHR rate is defined as the proportion of participants who achieve a CHR during or after study treatment initiation, as assessed by the investigator, according to the consensus guidelines for AL amyloidosis.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Number of participants with non-serious adverse events and serious adverse events

    Time frame: Up to approximately 24 months

  2. Number of participants with clinically significant changes in hematology, and chemistry parameters

    Time frame: Up to approximately 24 months

  3. Number of participants with ocular findings on ophthalmic examination

    Time frame: Up to approximately 24 months

  4. Organ response rate (OrRR)

    OrRR is defined as the proportions of participants who achieve confirmed organ response (cardiac, renal, or liver) in each organ as per consensus guidelines.

    Time frame: Up to approximately 5 years

  5. Duration of CHR

    Duration of CHR is defined for participants with CHR as the time from the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive disease.

    Time frame: Up to approximately 5 years

  6. Maximum plasma concentration (Cmax) of belantamab mafodotin

    Time frame: Up to 24 months

  7. Area under the concentration-time curve (AUC) of belantamab mafodotin

    Time frame: Up to 24 months

  8. Cmax of Cysteine maleimidocaproyl monomethyl auristatin F (cys-mcMMAF)

    Time frame: Up to 24 months

  9. AUC of cys-mcMMAF

    Time frame: Up to 24 months

  10. Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin

    Time frame: Up to approximately 24 months

  11. Titers of ADAs against belantamab mafodotin

    Time frame: Up to approximately 24 months

07

Study locations

16 of 16 sites recruiting
  • GSK Investigational Site
    Los Angeles, California 90048-1804, United States
    Recruiting
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
    Recruiting
  • GSK Investigational Site
    New Haven, Connecticut 06511, United States
    Recruiting
  • GSK Investigational Site
    Boston, Massachusetts 02118-2307, United States
    Recruiting
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • GSK Investigational Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • GSK Investigational Site
    Nashville, Tennessee 37232, United States
    Recruiting
  • GSK Investigational Site
    Salt Lake City, Utah 84112, United States
    Recruiting
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
    Recruiting
  • GSK Investigational Site
    Woolloongabba, Queensland 4102, Australia
    Recruiting
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
    Recruiting
  • GSK Investigational Site
    Box Hill, Victoria 3128, Australia
    Recruiting
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
    Recruiting
  • GSK Investigational Site
    Frankston, Victoria 3199, Australia
    Recruiting
  • GSK Investigational Site
    Liverpool, L7 8YA, United Kingdom
    Recruiting
  • GSK Investigational Site
    London, NW1 2BU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2033, 78 months after the start.

Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2025
First posted
Nov 5, 2025
StartActual
Jun 24, 2026
Primary completionEst.
Jan 12, 2033
CompletionEst.
Jan 12, 2033
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added — first site in United Kingdom
Show 11 added (7 United States, 2 Australia, 2 United Kingdom)
  • GSK Investigational Site · Los Angeles, United States
  • GSK Investigational Site · Aurora, United States
  • GSK Investigational Site · New Haven, United States
  • GSK Investigational Site · Boston, United States
  • GSK Investigational Site · Hackensack, United States
  • GSK Investigational Site · Nashville, United States
  • GSK Investigational Site · Salt Lake City, United States
  • GSK Investigational Site · Adelaide, Australia
  • GSK Investigational Site · Fitzroy, Australia
  • GSK Investigational Site · Liverpool, United Kingdom
  • GSK Investigational Site · London, United Kingdom
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • GSK Investigational Site · Woolloongabba, AustraliaContact person changed (no phone or email listed)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    11 sites added — first site in United Kingdom
    Show 11 added (7 United States, 2 Australia, 2 United Kingdom)
    • GSK Investigational Site · Los Angeles, United States
    • GSK Investigational Site · Aurora, United States
    • GSK Investigational Site · New Haven, United States
    • GSK Investigational Site · Boston, United States
    • GSK Investigational Site · Hackensack, United States
    • GSK Investigational Site · Nashville, United States
    • GSK Investigational Site · Salt Lake City, United States
    • GSK Investigational Site · Adelaide, Australia
    • GSK Investigational Site · Fitzroy, Australia
    • GSK Investigational Site · Liverpool, United Kingdom
    • GSK Investigational Site · London, United Kingdom
    Site contacts Changed at 1 site. See the sites
    Show the site
    • GSK Investigational Site · Woolloongabba, AustraliaContact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07224672
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 5, 2025
Start date
Jun 24, 2026
Primary completion
Jan 12, 2033 (estimated)
Completion
Jan 12, 2033 (estimated)
Last update
Nov 3, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab mafodotin · Cyclophosphamide · Bortezomib · Dexamethasone

Start the discussion